Literature DB >> 28751467

Recurrent Thrombosis in Patients with Antiphospholipid Syndrome Receiving Newer Oral Anticoagulants: A Case Report and Review of Literature.

Akanksha Joshi1, Jason Hong2, Chokkalingam Siva3.   

Abstract

We present the case of a patient with primary APS who had a recurrence of thrombotic event while on treatment with rivaroxaban and had to be restarted on warfarin. The current literature on recurrence of thrombotic events in patients with antiphospholipid syndrome (APS) treated with newer oral anticoagulants (NOAC) is also reviewed. Relevant case reports and case series were identified by searching the Medline database using the key words antiphospholipid syndrome, anticoagulants and names of the NOACs, and data on individual patients was abstracted. We identified several reports on the failure of newer anticoagulants in APS, as well as cases and clinical trial results reporting efficacy. We conclude that treatment strategies for APS should be tailored cautiously when using NOACs.
© 2017 Marshfield Clinic.

Entities:  

Keywords:  Anti-cardiolipin antibodies; Anti-phospholipid Syndrome; Anti-ß2-glycoprotein antibodies; Anticoagulants; Newer oral anticoagulant; Rivaroxaban; Warfarin

Mesh：

Substances：

Year:  2017        PMID： 28751467      PMCID： PMC5573519          DOI： 10.3121/cmr.2017.1349

Source DB:  PubMed          Journal:  Clin Med Res        ISSN： 1539-4182


  17 in total

1.  Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome.

Authors:  Rocco Vergallo; Aaron D Aguirre; Farhad Abtahian; Yoshiyasu Minami; Tsunenari Soeda; Yiannis S Chatzizisis; Kevin Croce; Ik-Kyung Jang
Journal:  Thromb Haemost       Date:  2015-10-01       Impact factor: 5.249

2.  The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases.

Authors:  Maksim Son; Ewa Wypasek; Magdalena Celinska-Lowenhoff; Anetta Undas
Journal:  Thromb Res       Date:  2015-02-02       Impact factor: 3.944

3.  New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome.

Authors:  Khine Win; George M Rodgers
Journal:  Am J Hematol       Date:  2014-09-02       Impact factor: 10.047

4.  Bipolar disorder, ischemic stroke, mitral valve vegetation and recurrent venous thrombosis due to antiphospholipid syndrome despite rivaroxaban.

Authors:  Jennifer Rokos; Maria Heger; Claudia Stöllberger; Josef Finsterer; Günther Laufer; Dominik Wiedemann
Journal:  Int J Cardiol       Date:  2016-06-23       Impact factor: 4.164

5.  The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.

Authors:  Katarzyna Malec; Tadeusz Góralczyk; Anetta Undas
Journal:  Thromb Res       Date:  2016-12-14       Impact factor: 3.944

6.  Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.

Authors:  V Pengo; A Banzato; E Bison; G Zoppellaro; S Padayattil Jose; G Denas
Journal:  Lupus       Date:  2015-10-13       Impact factor: 2.911

7.  Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.

Authors:  Jordan K Schaefer; Robert D McBane; David F Black; Lindsy N Williams; Kevin G Moder; Waldemar E Wysokinski
Journal:  Thromb Haemost       Date:  2014-08-14       Impact factor: 5.249

Review 8.  Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome.

Authors:  Nicolas Noel; Fabien Dutasta; Nathalie Costedoat-Chalumeau; Boris Bienvenu; Xavier Mariette; Loik Geffray; Damien Sene; Rafik Bekhadj Chaidi; Jean-Marie Michot; Olivier Fain; Luc Darnige; Annick Ankri; Patrice Cacoub; Jean-Charles Piette; David Saadoun
Journal:  Autoimmun Rev       Date:  2015-04-09       Impact factor: 9.754

9.  [Seronegative antiphospholipid syndrome, catastrophic syndrome, new anticoagulants: learning from a difficult case report].

Authors:  F Joalland; H de Boysson; L Darnige; A Johnson; C Jeanjean; S Cheze; A Augustin; C Auzary; L Geffray
Journal:  Rev Med Interne       Date:  2014-09-11       Impact factor: 0.728

10.  Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.

Authors:  Hannah Cohen; Beverley J Hunt; Maria Efthymiou; Deepa R J Arachchillage; Ian J Mackie; Simon Clawson; Yvonne Sylvestre; Samuel J Machin; Maria L Bertolaccini; Maria Ruiz-Castellano; Nicola Muirhead; Caroline J Doré; Munther Khamashta; David A Isenberg
Journal:  Lancet Haematol       Date:  2016-09       Impact factor: 18.959
View more
  2 in total

1.  [Decompensated heart failure as a result of a systemic disease].

Authors:  B Greiner; K Remde; H-M Lorenz; R Max
Journal:  Med Klin Intensivmed Notfmed       Date:  2019-04-11       Impact factor: 0.840

Review 2.  The use of direct acting oral anticoagulants in patients with COVID-19 infection.

Authors:  Ragia Aly; Sachin Gupta; Balraj Singh; Parminder Kaur; Kunhwa Kim; Sorab Gupta
Journal:  J Community Hosp Intern Med Perspect       Date:  2021-03-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.